Literature DB >> 73901

Bone-marrow transplantation in acute leukaemia.

R P Gale, S Feig, W G Ho, P Falk, D Winston, L S Young, G Opelz, G Opelz, A Tesler, R Sparkes, P R Graze, G Sarna, D W Golde, M C Territo, Y Bryson, T Gossett, F Naiem, F Fawzy, C Haskell, J L Fahey, M J Cline.   

Abstract

Survival in 33 patients with resistant leukaemia treated by marrow transplantation was compared with that of 37 matched patients treated by conventional and experimental chemotherapy. All patients in the transplant group were rendered free of detectable leukaemia for periods of from 36 days to more than 2 1/2 years, while only 6 patients in the chemotherapy group achieved a haematological remission. Overall survival in both groups was poor; however, 5 patients (15%) in the transplant group remain alive and in haematological remission 1--2 1/2 years after transplantation, while no patient in the chemotherapy group survived longer than 13 months. Bone-marrow transplantation appears to offer a small but distinct possibility of long-term survival in patients with acute leukaemia resistant to conventional therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 73901

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  3 in total

Review 1.  Progress in bone marrow transplantation in man.

Authors:  R P Gale
Journal:  Surv Immunol Res       Date:  1982

2.  [Controversial viewpoints on the use of historical controls: Is there an all-or-nothing law?].

Authors:  G Feifel
Journal:  Langenbecks Arch Chir       Date:  1981

3.  [Bone marrow transplantation for relapsed, acute leukaemia (author's transl)].

Authors:  H J Kolb; C Bender-Götze; E D Albert; R Haas; G Janka
Journal:  Klin Wochenschr       Date:  1981-03-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.